Literature DB >> 27940009

No protection of heart, kidneys and brain by remote ischemic preconditioning before transfemoral transcatheter aortic valve implantation: Interim-analysis of a randomized single-blinded, placebo-controlled, single-center trial.

Philipp Kahlert1, Heike Annelie Hildebrandt2, Polykarpos Christos Patsalis3, Fadi Al-Rashid4, Rolf Alexander Jánosi5, Felix Nensa6, Thomas Wilfried Schlosser7, Marc Schlamann8, Daniel Wendt9, Matthias Thielmann10, Eva Kottenberg11, Ulrich Frey12, Markus Neuhäuser13, Michael Forsting14, Heinz Günther Jakob15, Tienush Rassaf16, Jürgen Peters17, Gerd Heusch18, Petra Kleinbongard19.   

Abstract

BACKGROUND: Remote ischemic preconditioning (RIPC) reduces myocardial injury and improves clinical outcome in patients undergoing coronary revascularization, but only in the absence of propofol-anesthesia. We investigated whether RIPC provides protection of heart, kidneys and brain and improves outcome in patients undergoing transfemoral transcatheter aortic valve implantation (TF-TAVI).
METHODS: Patients undergoing TF-TAVI were randomized to receive RIPC (3cycles of 5min left upper arm ischemia and 5min reperfusion) or placebo. The primary endpoint was myocardial injury, reflected by the area under the curve for serum troponin I concentrations (AUC-TnI) over the first 72h. Secondary endpoints included the incidences of periprocedural myocardial infarction, delayed gadolinium enhancement on postprocedural cardiac MRI, acute kidney injury, periprocedural stroke, and the incidence and volume of new lesions on postprocedural cerebral MRI. All-cause and cardiovascular mortality and major adverse cardiac and cerebrovascular events (MACCE) were assessed over 1-year follow-up. A prespecified interim-analysis was performed after the last patient had completed 1-year follow-up (NCT02080299).
RESULTS: 100 consecutive patients were enrolled between September 2013 and June 2015. There were no significant between-group differences in the primary endpoint of peri-interventional myocardial injury (ratio RIPC/placebo AUC-TnI: 0.87, 95% CI: 0.57-1.34, p=0.53) or the secondary endpoints of cardiac, renal and cerebral impairment. There was no significant treatment effect in subgroup-analyses of patients undergoing cardiac or cerebral MRI. Mortality and MACCE did not differ. No RIPC-related adverse events were observed.
CONCLUSIONS: RIPC did neither protect heart, kidneys and brain nor improve clinical outcome in patients undergoing TF-TAVI.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Brain; Cardioprotection; Heart; Kidney; RIPC; TAVI

Mesh:

Year:  2016        PMID: 27940009     DOI: 10.1016/j.ijcard.2016.12.005

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

Review 2.  Remote ischaemic conditioning for preventing and treating ischaemic stroke.

Authors:  Wenbo Zhao; Jing Zhang; Mordechai G Sadowsky; Ran Meng; Yuchuan Ding; Xunming Ji
Journal:  Cochrane Database Syst Rev       Date:  2018-07-05

3.  Proteomics/phosphoproteomics of left ventricular biopsies from patients with surgical coronary revascularization and pigs with coronary occlusion/reperfusion: remote ischemic preconditioning.

Authors:  Nilgün Gedik; Marcus Krüger; Matthias Thielmann; Eva Kottenberg; Andreas Skyschally; Ulrich H Frey; Elke Cario; Jürgen Peters; Heinz Jakob; Gerd Heusch; Petra Kleinbongard
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

4.  Effect of Remote Ischemic Conditioning in Patients With Takotsubo Syndrome After Acute Stroke: Study Protocol for a Randomized Controlled Trial.

Authors:  Tao Wang; Yueqiao Xu; Ning Wang; Meng Qi; Weitao Cheng; Xin Qu
Journal:  Front Neurol       Date:  2020-04-28       Impact factor: 4.003

5.  Remote Ischemic Preconditioning Neither Improves Survival nor Reduces Myocardial or Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI).

Authors:  Mandy Flechsig; Tobias F Ruf; Willi Troeger; Stephan Wiedemann; Silvio Quick; Karim Ibrahim; Christian Pfluecke; Akram Youssef; Krunoslav M Sveric; Robert Winzer; Frank R Heinzel; Axel Linke; Ruth H Strasser; Kun Zhang; Felix M Heidrich
Journal:  J Clin Med       Date:  2020-01-07       Impact factor: 4.241

6.  Remote ischemic conditioning for the prevention of contrast-induced acute kidney injury in patients undergoing intravascular contrast administration: a meta-analysis and trial sequential analysis of 16 randomized controlled trials.

Authors:  Chang-Cheng Zhou; Wen-Tao Yao; Yu-Zheng Ge; Lu-Wei Xu; Ran Wu; Xiao-Fei Gao; Kai-Wei Song; Xiao-Min Jiang; Min Wang; Wen-Juan Huang; Yun-Peng Zhu; Liang-Peng Li; Liu-Hua Zhou; Zhong-Le Xu; Sheng-Li Zhang; Jia-Geng Zhu; Wen-Cheng Li; Rui-Peng Jia
Journal:  Oncotarget       Date:  2017-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.